ArticleCell communication and signaling : CCS2023

The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin's lymphoma tumor growth by promoting apoptosis and autophagy.

Yan Lv et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.